L26/P-424 Ovarian stimulation outcomes for fertility preservation in breast cancer patients according to hormone receptor status
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Fedhila und 10 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Study question Does the immunohistochemical profile of breast cancer influence the ovarian response to stimulation in the context of urgent fertility preservation? Summary answer A significantly reduced number of cumulus–oocyte complexes and metaphase II oocytes was observed in patients with triple-negative breast cancer after ovarian stimulation. What is known already Breast cancer is the most common malignancy among women, with approximately 2.3 million new cases worldwide in 2020. Advances in chemotherapy and radiotherapy have markedly improved survival, with 5-year relative survival rates approaching 90%. Consequently, fertility preservation has become a major clinical concern for young breast cancer survivors. Oocyte or embryo vitrification following controlled ovarian stimulation is currently the standard fertility preservation strategy. The immunohistochemical profile of breast cancer, together with tumor stage and grade, plays a key role in assessing tumor aggressiveness, prognosis, and guiding treatment decisions. However, its impact on ovarian stimulation response remains controversial. Study design, size, duration We conducted a retrospective single-center study including 116 patients who underwent urgent fertility preservation between 2019 and 2024 at a university hospital. Participants/materials, setting, methods Patients were stratified by estrogen (ER) and progesterone (PR) receptor status, with ER−/PR−/HER2− tumors defined as triple-negative breast cancer (TNBC). Comparative analyses were conducted between (1) ER-positive and ER-negative patients, and (2) TNBC and non-TNBC tumors . A standard GnRH antagonist random-start protocol was used for ovarian stimulation. And aromatase inhibitor (5 mg/day) was administered to all patients during ovarian stimulation. The primary outcome was the number of mature oocytes retrieved. Main results and the role of chance A total of 116 ovarian stimulation cycles were included in the analysis. No significant differences were observed between the estrogen receptor (ER)-positive (n = 75) and ER-negative (n = 41) groups regarding ovarian response, as assessed by the number of cumulus–oocyte complexes (COCs) retrieved [11 (IQR: 7–17) vs. 10 (IQR: 4–21), respectively] and the number of mature oocytes obtained after stimulation [7 (IQR: 4–13) vs. 5 (IQR: 3–11), respectively]. In contrast, patients with triple-negative breast cancer (TNBC; n = 28) exhibited a significantly reduced ovarian response compared with the non-TNBC group, with a lower number of COCs retrieved [6 (IQR: 6–13) vs. 12 (IQR: 7–18), p = 0.015]. Similarly, the number of mature oocytes was significantly lower in the TNBC group [4 (IQR: 3–7)] compared with the non-TNBC group [7 (IQR: 4–13), p = 0.015] Limitations, reasons for caution The retrospective design and relatively small sample size may limit the interpretation and generalizability of these findings. Potential selection bias and missing data inherent to retrospective analyses should also be considered. Therefore, the results should be interpreted with caution and confirmed in larger, prospective studies. Wider implications of the findings Ovarian response to stimulation appears to vary by breast cancer immunohistochemical subtype, especially in TNBC. These findings may support more tailored fertility preservation counseling. Prospective studies with larger cohorts are required to confirm these results. Trial registration number No
Zitieren
APA
Fedhila, A., Braham, M., Guermazi, H., Zouari, M., Chtourou, S., Fadhlaoui, A., Mefteh, M. B., Kacem, K., Zoghlami, H., Chakroun, N., & Kdous, M. (2026). L26/P-424 Ovarian stimulation outcomes for fertility preservation in breast cancer patients according to hormone receptor status. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.758
Vancouver
Fedhila A, Braham M, Guermazi H, Zouari M, Chtourou S, Fadhlaoui A, et al. L26/P-424 Ovarian stimulation outcomes for fertility preservation in breast cancer patients according to hormone receptor status. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.758
BibTeX
@article{Fedhila2026,
author = {Fedhila, A. and Braham, M. and Guermazi, H. and Zouari, M. and Chtourou, S. and Fadhlaoui, A. and Mefteh, M. Ben and Kacem, K. and Zoghlami, H. and Chakroun, N. and Kdous, M.},
title = {L26/P-424 Ovarian stimulation outcomes for fertility preservation in breast cancer patients according to hormone receptor status},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.758}
}
EUVIMED